~~<i id='EE2E55C943'><strike id='EE2E55C943'><tt id='EE2E55C943'><pre id='EE2E55C943'></pre></tt></strike></i>~~

Home» explore» comprehensive

comprehensive

author：Wikipedia 2025-10-02 08:12:46 Page View：76373

Editor’s note: A recording of the event is embedded below.

After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

Featured Speakers

Irena Melnikova, Ph.D., partner, Pfizer Ventures
Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Air quality improving but still lags in Black, Hispanic communities
Next article： Sports medicine is finally prioritizing gender equality

explore

Drug repurposing or repositioning? The language matters

AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

PEPFAR is under serious threat — and so is global health

AhospitalinNairobi,Kenya,thatisabeneficiaryoftheglobalhealthinitiativePEPFAR.BrentStirton/GettyImage

Virginia high school admissions case could be legal follow

3:24DemonstratorsprotestoutsideoftheSupremeCourtinWashington,Thursday,June29,2023,aftertheSupremeCou

Long Covid needs a new name — and a new frame

AdvocatesforpeoplewithlongCovidandmyalgicencephalomyelitis/chronicfatiguesyndromehostaninstallationo